Hamamelis liquid extract 81.54% gel
Available from pharmacies, supermarkets, and retail outlets
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Suspected adverse reactions reported for Hamamelis
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
Search EudraVigilance database
Browse substances A–Z in the European adverse reaction database
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
2 branded products available
MHRA licensed products
View all licensed products for Hamamelis on the MHRA register
Witch Doctor gel
Therapeutically similar medicines
Other
(2)Eye, ear & nasal
(2)Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0.
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 3 · Randomised trials: 1 · 1973–2026
Showing the 50 most relevant studies, sorted by most relevant.
Kloter E, Albanese F, Schweighoffer R, et al.
2023
- Plants, Medicinal
- Dermatitis, Atopic
- Phytotherapy
ObjectivesAlthough skin disorders in children and adolescents are increasingly treated with phytotherapies in practice, there are very few studies investigating this topic, and no systematic review exists that summarizes the current state of research. This review examines which herbal medicines show to be effective to treat atopic dermatitis, diaper dermatitis, and skin lesions or wounds.MethodsClinical studies were searched according to PRISMA-guidelines in the medical databases of PubMed, EMBASE, and CINAHL and summarised in a systematic review.ResultsAmong the 429 articles screened, 17 studies with a total of 2358 participants were identified that suited our inclusion criteria. Thereof seven studies each on the treatment of atopic dermatitis and skin lesions or wounds and three on diaper dermatitis. The phytotherapeutics investigated were based on the following herbs: Evening primrose, blackcurrant, polypodium leucotomos, calendula, aloe vera, chamomile, comfrey, hamamelis, olive, hypericum, neem, white oak, and myrrh. They have mainly been analysed in randomized controlled trials, but also in (long-term) observational studies, prospective trials and case series.ConclusionsBased on the application of the Jadad score, eight out of 17 of the studies examined were of low quality. Yet we found some indication that evening primrose oil may be effective for treating atopic dermatitis in children, while comfrey appears to have a positive effect on wound healing. Interestingly, none of the studies found positive effects for treating skin disorders with aloe vera or chamomile.
Abstract licence: CC BY
Döndü Sevimli Güler, Gülşen Vural, Zekiye Turan, et al.
Breastfeeding Medicine, 2025
- Milk, Human
- Diaper Rash
- Single-Blind Method
A. Rostami-Vartooni, M. Nasrollahzadeh, M. Alizadeh
Journal of Alloys and Compounds, 2016
Magdalena Wójciak, Wiktoria Pacuła, Ireneusz Sowa, et al.
Molecules, 2025
- Plant Extracts
- Skin Care
- Skin
Hamamelis virginiana L. (witch hazel) is a traditionally used medicinal plant, well-known for its dermatological applications. The plant’s bark and leaves contain a rich array of bioactive compounds, including phenolic acids, flavonoids, catechins, proanthocyanidins, and tannins, many of which exhibit antimicrobial, anti-inflammatory, antioxidant, and wound-healing properties. These activities have been verified by numerous in vitro and in vivo studies, as well as limited clinical trials. The H. virginiana extracts have demonstrated effectiveness against bacteria, fungi, and some viruses. Moreover, the extracts exert anti-inflammatory effects by modulating cytokine expression and NF-κB signaling, improve skin regeneration, and protect against UV-induced damage and pollution. This review highlights H. virginiana as a complex botanical resource to be used in dermatology and cosmetology and shows that current research offers encouraging results for its future therapeutic use, especially in skin treatment.
Abstract licence: CC BY 4.0
Admuthe NB, Karajgi S, Uikey J, et al.
2025
Hemorrhoids are an anorectal problem that is prevalent and commonly managed with corticosteroids, analgesics, and phlebotonics. These conventional treatments are, however, only temporary in serving relief and come with adverse side effects when used long-term. Alternative herbal remedies, created from traditional medicine with all the evidence of their pharmacological action, promise good results. The effectiveness of various botanicals with the potential of being anti-inflammatory, venotonic, astringent, antioxidant, and wound healing in alleviating hemorrhoidal symptoms is discussed in this review. Therapeutically notable plants such as witch hazel (Hamamelis virginiana), horse chestnut (Aesculus hippocastanum), and triphala have shown beneficial therapeutic effects on pain, bleeding, and swelling, as well as preventing recurrence. Moreover, Triphala Guggulu and Pilex are polyherbal formulations that offer synergistic benefits in addition to foods rich in polyphenols and the dietary compound, rutin. These promising findings have so far faced challenges related to the standardization, quality control, and clinical validation. The incorporation of these herbal therapies into clinical practice is a well-tolerated holistic approach to the management of hemorrhoids, which requires further investigation to gain evidence-based validation.
Abstract licence: CC BY
Qianqian Kong, Huanhuan Zhang, Zhenluo Yuan, et al.
ACS Sustainable Chemistry & Engineering, 2020
A. Deters, A. Dauer, Esther Schnetz, et al.
Phytochemistry, 2001
Linda L. Theisen, Clemens A. J. Erdelmeier, Gilles A. Spoden, et al.
PLoS ONE, 2014
Antiviral activity has been demonstrated for different tannin-rich plant extracts. Since tannins of different classes and molecular weights are often found together in plant extracts and may differ in their antiviral activity, we have compared the effect against influenza A virus (IAV) of Hamamelis virginiana L. bark extract, fractions enriched in tannins of different molecular weights and individual tannins of defined structures, including pseudotannins. We demonstrate antiviral activity of the bark extract against different IAV strains, including the recently emerged H7N9, and show for the first time that a tannin-rich extract inhibits human papillomavirus (HPV) type 16 infection. As the best performing antiviral candidate, we identified a highly potent fraction against both IAV and HPV, enriched in high molecular weight condensed tannins by ultrafiltration, a simple, reproducible and easily upscalable method. This ultrafiltration concentrate and the bark extract inhibited early and, to a minor extent, later steps in the IAV life cycle and tannin-dependently inhibited HPV attachment. We observed interesting mechanistic differences between tannin structures: High molecular weight tannin containing extracts and tannic acid (1702 g/mol) inhibited both IAV receptor binding and neuraminidase activity. In contrast, low molecular weight compounds (<500 g/mol) such as gallic acid, epigallocatechin gallate or hamamelitannin inhibited neuraminidase but not hemagglutination. Average molecular weight of the compounds seemed to positively correlate with receptor binding (but not neuraminidase) inhibition. In general, neuraminidase inhibition seemed to contribute little to the antiviral activity. Importantly, antiviral use of the ultrafiltration fraction enriched in high molecular weight condensed tannins and, to a lesser extent, the unfractionated bark extract was preferable over individual isolated compounds. These results are of interest for developing and improving plant-based antivirals.
Abstract licence: CC BY 4.0
C. A. E. C. A. Erdelmeier13, J. C. J. J. Cinati, H. Rabenau, et al.
Planta Medica, 1996
Korgaonkar A, Han C, Lemire AL, et al.
2021
- Host-Parasite Interactions
- Aphids
- Hamamelis
In an elaborate form of inter-species exploitation, many insects hijack plant development to induce novel plant organs called galls that provide the insect with a source of nutrition and a temporary home. Galls result from dramatic reprogramming of plant cell biology driven by insect molecules, but the roles of specific insect molecules in gall development have not yet been determined. Here, we study the aphid Hormaphis cornu, which makes distinctive "cone" galls on leaves of witch hazel Hamamelis virginiana. We found that derived genetic variants in the aphid gene determinant of gall color (dgc) are associated with strong downregulation of dgc transcription in aphid salivary glands, upregulation in galls of seven genes involved in anthocyanin synthesis, and deposition of two red anthocyanins in galls. We hypothesize that aphids inject DGC protein into galls and that this results in differential expression of a small number of plant genes. dgc is a member of a large, diverse family of novel predicted secreted proteins characterized by a pair of widely spaced cysteine-tyrosine-cysteine (CYC) residues, which we named BICYCLE proteins. bicycle genes are most strongly expressed in the salivary glands specifically of galling aphid generations, suggesting that they may regulate many aspects of gall development. bicycle genes have experienced unusually frequent diversifying selection, consistent with their potential role controlling gall development in a molecular arms race between aphids and their host plants.
Abstract licence: CC BY
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Scientific data (pharmacology, interactions, ADME) is not yet available for this medicine. Clinical sections are sourced from the NHS dm+d database.